Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives.
combination therapy
hepatocellular carcinoma
immunotherapy
predictive markers
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
18 Oct 2020
18 Oct 2020
Historique:
received:
23
09
2020
revised:
13
10
2020
accepted:
15
10
2020
entrez:
21
10
2020
pubmed:
22
10
2020
medline:
22
10
2020
Statut:
epublish
Résumé
Immune checkpoint inhibitors (ICIs) represent a promising treatment for many kinds of cancers, including hepatocellular carcinoma (HCC). The rationale for using ICIs in HCC is based on the immunogenic background of hepatitis and cirrhosis and on the observation of high programmed death-ligand 1 (PD-L1) expression and tumor-infiltrating lymphocytes in this cancer. Promising data from phase I/II studies in advanced HCC, showing durable objective response rates (~20% in first- and second-line settings) and good safety profile, have led to phase III studies with ICIs as single agents or in combination therapy, both in first and second line setting. While the activity of immunotherapy agents as single agents seems to be limited to an "ill-defined" small subset of patients, the combination of the anti PD-L1 atezolizumab and anti-vascular endothelial growth factor bevacizumab revealed a benefit in the outcomes when compared to sorafenib in the first line. In addition, the activity and efficacy of the combinations between anti-PD-1/anti-PD-L1 antibody and other ICIs, tyrosine kinase inhibitors, or surgical and locoregional therapies, has also been investigated in clinical trials. In this review, we provide an overview of the role of ICIs in the management of HCC with a critical evaluation of the current status and future directions.
Identifiants
pubmed: 33080958
pii: cancers12103025
doi: 10.3390/cancers12103025
pmc: PMC7603151
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Clin Cancer Res. 2009 Feb 1;15(3):971-9
pubmed: 19188168
Lancet Oncol. 2018 Jul;19(7):940-952
pubmed: 29875066
Oncoimmunology. 2017 Sep 14;7(1):e1364828
pubmed: 29296515
Hepatology. 1993 Jun;17(6):1127-52
pubmed: 8514264
Liver Cancer. 2021 Jun;10(3):249-259
pubmed: 34239811
Hepatology. 2013 Apr;57(4):1448-57
pubmed: 23174905
Hepatol Res. 2018 Jul;48(8):622-634
pubmed: 29734514
Acta Pharm Sin B. 2020 Mar;10(3):414-433
pubmed: 32140389
Liver Transpl. 2004 Feb;10(2 Suppl 1):S115-20
pubmed: 14762851
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Lancet Oncol. 2019 Feb;20(2):282-296
pubmed: 30665869
Science. 2018 May 25;360(6391):
pubmed: 29798856
J Immunother Cancer. 2019 Jul 23;7(1):193
pubmed: 31337439
Cancers (Basel). 2019 Oct 30;11(11):
pubmed: 31671581
Cell Mol Immunol. 2016 May;13(3):267-76
pubmed: 27063467
Cancer Res. 2013 Apr 15;73(8):2435-44
pubmed: 23423978
Int J Cancer. 2011 Feb 15;128(4):887-96
pubmed: 20473887
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv238-iv255
pubmed: 30285213
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7
pubmed: 12218188
J Hematol Oncol. 2018 Mar 15;11(1):39
pubmed: 29544515
Lancet. 2018 Mar 31;391(10127):1301-1314
pubmed: 29307467
Acta Pharmacol Sin. 2010 Nov;31(11):1409-20
pubmed: 20953207
Nat Immunol. 2013 Oct;14(10):996-1006
pubmed: 24048121
J Clin Invest. 2004 Sep;114(5):701-12
pubmed: 15343389
Cancer Res. 2009 Oct 15;69(20):8067-75
pubmed: 19826049
Lancet Oncol. 2015 Oct;16(13):1344-54
pubmed: 26361969
Expert Rev Mol Diagn. 2019 Jun;19(6):517-529
pubmed: 31079502
Eur J Immunol. 2006 Jun;36(6):1413-22
pubmed: 16708397
Gastroenterology. 2018 Jan;154(1):128-139
pubmed: 28989060
Nat Genet. 2014 Dec;46(12):1267-73
pubmed: 25362482
J Hepatol. 2017 Sep 18;:
pubmed: 28923358
J Clin Oncol. 2020 Jan 20;38(3):193-202
pubmed: 31790344
N Engl J Med. 2018 Jul 05;379(1):54-63
pubmed: 29972759
Oncology. 2014;87 Suppl 1:22-31
pubmed: 25427730
J Hepatol. 2016 May;64(5):1090-1098
pubmed: 26809111
Cancer Treat Rev. 2011 May;37(3):212-20
pubmed: 20724077
Nat Rev Immunol. 2010 Nov;10(11):753-66
pubmed: 20972472
J Hepatol. 2017 Jul;67(1):173-183
pubmed: 28323121
Hepatology. 2015 Aug;62(2):440-51
pubmed: 25678263
Lancet Gastroenterol Hepatol. 2017 Aug;2(8):565-575
pubmed: 28648803
Nat Rev Immunol. 2008 Jun;8(6):467-77
pubmed: 18500231
J Hepatol. 2019 May;70(5):999-1007
pubmed: 30738077
Cell. 2015 Apr 9;161(2):205-14
pubmed: 25860605
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
J Clin Oncol. 2016 Apr 1;34(10):e90-2
pubmed: 25245441
Science. 2006 Sep 29;313(5795):1972-5
pubmed: 16931720
Gastroenterology. 2015 Oct;149(5):1226-1239.e4
pubmed: 26099527
Hepatology. 2014 Nov;60(5):1776-82
pubmed: 24912948
Clin Cancer Res. 2019 Jan 15;25(2):515-523
pubmed: 30348638
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
J Clin Oncol. 2021 Sep 20;39(27):2991-3001
pubmed: 34292792
Hepatology. 2011 Apr;53(4):1206-16
pubmed: 21480325
Expert Rev Clin Pharmacol. 2019 May;12(5):453-470
pubmed: 30907177
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
Nature. 2007 Feb 15;445(7129):771-5
pubmed: 17220874
Transplantation. 2001 Aug 15;72(3):449-54
pubmed: 11502975
Science. 2018 Jan 5;359(6371):97-103
pubmed: 29097493
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
Int Immunopharmacol. 2018 Sep;62:29-39
pubmed: 29990692
Gastroenterology. 2016 Dec;151(6):1155-1163.e2
pubmed: 27575820
Liver Transpl. 2008 Mar;14(3):272-8
pubmed: 18306328
Nat Commun. 2016 Feb 17;7:10501
pubmed: 26883990
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Cancer Discov. 2016 Feb;6(2):202-16
pubmed: 26645196
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Blood. 2009 May 7;113(19):4556-65
pubmed: 19246340
J Hepatol. 2013 Jul;59(1):81-8
pubmed: 23466307
Clin Cancer Res. 2018 Apr 1;24(7):1518-1524
pubmed: 29138342
J Exp Clin Cancer Res. 2018 May 29;37(1):110
pubmed: 29843754
Nat Commun. 2016 Aug 30;7:12624
pubmed: 27571927
Hepatology. 2014 Feb;59(2):567-79
pubmed: 23960017
Cancer Res Treat. 2017 Jan;49(1):246-254
pubmed: 27456947